Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2019

A fatal case of disseminated microsporidiosis due to Anncaliia
algerae in a renal and pancreas allograft recipient
Neil W. Anderson
Washington University School of Medicine in St. Louis

Atis Muehlenbachs
Center for Disease Control and Prevention

Sana Arif
Duke University

Jackrapong Bruminhent
Mahidol University

Paul J. Deziel
Mayo Clinic

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Anderson, Neil W.; Muehlenbachs, Atis; Arif, Sana; Bruminhent, Jackrapong; Deziel, Paul J.; Razonable,
Raymund R.; Wilhelm, Mark P.; Metcalfe, Maureen G.; Qvarnstrom, Yvonne; and Pritt, Bobbi S., ,"A fatal case
of disseminated microsporidiosis due to Anncaliia algerae in a renal and pancreas allograft recipient."
Open Forum Infectious Diseases. 6,7. . (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8227

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Neil W. Anderson, Atis Muehlenbachs, Sana Arif, Jackrapong Bruminhent, Paul J. Deziel, Raymund R.
Razonable, Mark P. Wilhelm, Maureen G. Metcalfe, Yvonne Qvarnstrom, and Bobbi S. Pritt

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/8227

Open Forum Infectious Diseases
BRIEF REPORT

Neil W. Anderson,1,a Atis Muehlenbachs,2,b Sana Arif,3 Jackrapong Bruminhent,4
Paul J. Deziel,5 Raymund R. Razonable,5,6 Mark P. Wilhelm,5,6 Maureen G. Metcalfe,2,c
Yvonne Qvarnstrom,7 and Bobbi S. Pritt1,6
1

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo
Clinic, Rochester, Minnesota; 2Division of High-Consequence Pathogens and Pathology,
National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease
Control and Prevention, Atlanta, Georgia; 3Division of Infectious Diseases, Department
of Medicine, Duke University School of Medicine, Durham, North Carolina; 4Division of
Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital,
Mahidol University, Bangkok, Thailand; 5William J. von Liebig Center for Transplantation and
Clinical Regeneration, Mayo Clinic, Rochester, Minnesota; 6Division of Infectious Diseases,
Department of Medicine, Mayo Clinic, Rochester, Minnesota; 7Division of Parasitic Diseases
and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta,
Georgia

Key words: Brachiola; immunocompromised; microsporidiosis; microsporidia; Nosema; opportunistic.
CASE REPORT

A 60-year-old male pancreas and renal allograft recipient
presented for evaluation of a painless, nonpruritic papular rash
on his lower extremities. Seventeen months prior, he received
a living unrelated donor kidney transplant for end-stage renal
disease secondary to ANCA-associated antiglomerular basement membrane disease, followed 7 months later by a pancreas
allograft transplant for type 1 diabetes mellitus. He received
alemtuzumab and thymoglobulin for induction therapy after
renal and pancreas transplants, respectively, followed by prednisone, mycophenolate mofetil and tacrolimus for maintenance
immunosuppression. His posttransplant course was complicated by acute pancreas allograft rejection requiring increased
dose of prednisone, severe hypogammaglobulinemia requiring
monthly intravenous immunoglobulin, and severe lymphopenia
(CD4+ T helper cells of 0–5 cells/µL). He experienced multiple
opportunistic infectious complications, initially with delayed
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onset primary cytomegalovirus pneumonitis and retinitis (with
virologic recurrences), followed by influenza A pneumonia
with prolonged viral shedding, and recurrent dermatomal
zoster. Subsequently, he developed overlapping infections due
to Aspergillus sp. (invasive rhinosinusitis), Lichtheimia (Absidia)
sp. (pneumonia), and Mycobacterium malmoense (bloodstream
infection and pneumonia). At the time of his evaluation, he was
receiving liposomal amphotericin B and posaconazole for invasive aspergillus sinusitis and Lichtheimia pneumonia, and
clarithromycin, rifabutin, and ethambutol for Mycobacterium
malmoense infection. In addition, he was receiving prophylaxis
with trimethoprim-sulfamethoxazole and valganciclovir.
A punch biopsy of the skin lesion in the lower extremity
showed extensive vascular thrombosis and dermal necrosis.
Clusters of small, 2 to 4 µm long, oval organisms (Figure 1) were
observed in the dermis with a scant associated lymphohistiocytic
inflammatory response. Organisms were located within cells and
lumens of eccrine ducts and within smooth muscle and lumens
of dermal arterioles. No budding was identified. A small number
of organisms were positive with Grocott-Gomori’s methenamine
silver (GMS) stain. Based on this appearance, a presumptive diagnosis of histoplasmosis was made, and he was continued on
liposomal amphotericin B and posaconazole. Subsequent fungal
cultures from skin biopsies were negative, and serologic and
urine antigen testing for Histoplasma capsulatum were negative. H. capsulatum PCR (polymerase chain reaction) on lesional
tissue also was negative. His rash remained unchanged on
antifungal therapy and he subsequently developed ulcerations
over the tip of his tongue with a yellowish eschar (Figure 1).
Biopsy of the lesions showed similar organisms to those previously described.
During this time, he experienced profound pancytopenia.
Bone marrow biopsy showed hypocellular bone marrow with
no evidence of infection. Over concerns for aplastic anemia,
he was given methylprednisolone intravenously followed by a
course of prednisone therapy and subsequently cyclosporine,
during which his rash worsened and he developed necrotic
lesions on his fingertips (Figure 1). Biopsy of a finger lesion
once again highlighted small organisms similar to those previously observed with focal GMS positivity. Organisms also were
noted to be strongly Gram positive (Twort’s Gram stain), focally positive with the Ziehl-Neelsen stain, and focally birefringent with polarized light (Figure 1). Distinctive polar dot-like
positivity was observed using Periodic acid–Schiff (PAS) stain
without amylase. At this point, expert review by pathologists
specializing in the pathology of infectious diseases at Mayo
Clinic and the Centers for Disease Control and Prevention’s
(CDC) Infectious Diseases Pathology Branch and Parasitic
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Figure 1. The patient developed several clinical manifestations of disseminated
microsporidiosis due to Anncaliia algerae, including (A) ulcerative fingers and (B)
oral lesions, as well as ulcerative intranasal lesions and a diffuse papular rash
of the lower extremities (not shown). By light microscopic examination, spores
were visible using (C) routine hematoxylin and eosin staining, (D) focally positive
by Gomori methenamine silver stain, and (E) strongly Gram-positive by Gram stain.
(F) The Periodic acid–Schiff stain showed polar dot-like positivity, which is characteristic of microsporidial spores. Spores also were stained bright red using (G)
the Ryan blue modified trichrome stain for microsporidia. (H) Electron microscopy
showed features of a Nosema-like microsporidia, including large size, a thick cell
wall, and a single row of polar filaments (arrow). Scale bars represent 20 µm, except
in (H) in which the scale bar is 500 nm.

Diseases Branch (Atlanta, GA) concluded that microsporidiosis
was the likely diagnosis. Ryan blue modified trichrome stain on
sputum and urine showed positively-staining structures (4 µm
long) consistent with microsporidial spores. Electron microscopy and molecular studies at the CDC confirmed the diagnosis
of microsporidiosis. Based on ultrastructure features (Figure
1), including organism size, cell wall thickness, and number of
polar tubule coils, the organism was identified as a Nosema-like
organism. Molecular amplification and sequencing identified
the organisms specifically as Anncaliia (formerly Brachiola,
Nosema) algeriae. A diagnosis of systemic disease was made
based on the presence of microsporidia spores in the lower
extremity, finger and tongue biopsies, as well as in urine and
sputum samples.
The patient was started on albendazole, 400 mg twice daily,
for disseminated microsporidiosis; unfortunately, his skin rash
continued to progress, and his lesions on his fingers and oral
cavity became necrotic with eschar formation. In addition to
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albendazole, itraconazole and clindamycin were added for
potential enhanced activity [1]. Approval was received to use
fumagillin from the US Food and Drug Administration under
an investigational use protocol, but the drug unfortunately was
not available from the manufacturer. At this point, the patient`s
immunosuppressive medications were discontinued to enable
his immune system to better mount a response to the infection.
He continued to be debilitated. Because of his declining condition and nonresponse to antimicrobial therapy despite the discontinuation of all immunosuppressive regimens, he decided
for comfort care. He expired 2 days after transition to comfort
measures, 5 months after his clinical presentation.
The microsporidia are a large group of parasitic fungi
encompassing several genera. They are obligate intracellular
eukaryotic organisms that survive extracellularly by forming a
spore with a thick cell wall. This spore contains a polar tubule,
a coiled extrusion apparatus that the organism uses to inject its
contents into a host cell. Once inside a host cell, intracellular
replication leads to production of more spores that are released
by cell rupture.
Microsporidia spores are readily identified in typical tissue,
stool, or respiratory specimens. They are small (0.8–4 µm in
greatest dimension) and are highlighted in direct specimen
preparations using modifications to the trichrome stain that
increase the chromotrope 2R component (eg, Ryan blue modified trichrome stain), allowing the stain to penetrate the thick
cell wall [2]. The organisms also can be visualized on calcofluor
white stain or using specific direct fluorescent antibody
preparations. In formalin-fixed, paraffin-embedded tissues
sections, spores are partially acid fast, stain variably with GMS,
exhibit birefringence with polarized light, and have a polar dotlike positivity using the PAS stain [3, 4] that corresponds to the
polar tubule. Electron microscopy and, recently, nucleic acid
amplification tests are used to identify the infecting genus and
species [5].
Of the many different microsporidia capable of causing
human disease, the 2 most common, Encephalitozoon
intestinalis and Enterocytozoon bieneusi, are associated with
diarrhea in immunosuppressed patients. These organisms
also can cause disease in other body sites, including the lungs,
kidneys, and central nervous system. Although their spores are
small (<2 µm in greatest dimension), the spores of other genera
such as Anncaliia are larger (≤4 µm) and may be confused with
small yeasts. As such, initial misdiagnosis of microsporidia infection as disseminated fungal infection has been reported in
the literature [6]. This was observed in our patient as well, because he was initially misdiagnosed as having disseminated
histoplasmosis due to the large size of the observed organisms
and focal GMS positivity. However, 2 major aspects of this
case were not supportive of this diagnosis: he was already receiving liposomal amphoterin B and posaconazole (both
active against H. capsulatum) and he had negative fungal

and pancytopenic. This severely immunosuppressed state is phenotypically manifested by sequential and concurrent infections
with classic and unusual opportunistic pathogens, including, in
this case, lesser known species of microsporidia [12].
In summary, we present a fatal case of disseminated
microsporidiosis due to A. algerae in a highly immunocompromised kidney and pancreas allograft recipient. Microsporidiosis
was initially misdiagnosed as H. capsulatum due to its
overlapping morphologic features. Clinicians, pathologists, and
microbiologists should consider microsporidiosis in their differential diagnosis, particularly in profoundly immunocompromised hosts, and seek expert consultation when appropriate.
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culture, H. capsulatum urine antigen, serology, and PCR. These
prompted additional expert review at Mayo Clinic and the CDC,
which allowed for definitive identification of microsporidiosis.
Electron microscopy and molecular amplification identified the
organisms as A. algerae.
A. algerae is an insect pathogen, infecting primarily
mosquitos [7]. This organism only rarely has been reported to
cause disease in humans. As of 2018, a review of published literature revealed a total of 7 cases isolated to Australia and North
America. These include cases in patients following stem cell
and solid organ transplantation. Disease typically manifests as
skeletal muscle myositis, with over half of patients experiencing
central nervous system or cardiac involvement [6]. Involvement
of the vocal chords and bulbar muscles also has been described,
leading to dysphagia and aspiration pneumonia [6, 8, 9].
The mechanism of transmission, including potential role of
mosquitoes, is unknown.
An important feature common to our case and in previously
reported cases is the severity of disease. This is likely attributed to
the highly compromised immune status of the patients. Moreover,
although albendazole typically is effective for other causes of
microsporidiosis, a proportion of infections caused by A. algerae
appear not to respond as efficiently to this drug [10, 11]. In the absence of controlled studies examining the efficacy of albendazole
for this species in comparison to other microsporidia, it is difficult
to attribute these instances of treatment failure to albendazole resistance versus other factors, such as differences in host immunity, disease burden, and organism virulence. Other less widely
available drugs might enhance effect, such as fumagillin and
nikkomycin Z [11]. Efforts to acquire fumagillin from the manufacturer were unsuccessful. Discontinuation of the immunosuppressive drugs should be strongly considered in cases when
antimicrobial therapy is very limited, particularly in recipients of
kidney and pancreas allografts, in whom alternative treatments
(dialysis and insulin, respectively) are available. This approach
was not possible in this case as the diagnosis of microsporidiosis
occurred later in the disease course.
Clinical familiarity with microsporidia is largely due to HIVassociated cases prior to highly active antiretroviral therapy.
These cases often were caused by a narrow spectrum of species
and typically resulted in diarrhea with occasional extra-intestinal
manifestations. In contrast, only very few cases are reported in nonHIV immunocompromised hosts, such as transplant recipients.
Our transplant patient was significantly immunocompromised,
even when compared to the typical solid organ transplant recipient—he was profoundly T-cell depleted, hypogammaglobulinemic,

